- 150 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
eBook - ePub
Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC
About this book
Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer.
This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer.
- Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented
- Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors
- Encompasses the current state of affairs in clinical trials to address resistance
Frequently asked questions
Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC by Anthony Faber in PDF and/or ePUB format, as well as other popular books in Biological Sciences & Biology. We have over one million books available in our catalogue for you to explore.
Information
Table of contents
- Cover
- Front Matter
- Table of Contents
- Copyright
- Cover Image Insert
- Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
- About the Series Editor
- Aims and Scope of the Volume
- About the Volume Editor
- Preface
- Contributors
- List of Illustrations
- List of Tables
- Chapter 1 : Historical development of EGFR-targeted therapy
- Chapter 2 : The development and implementation of EGFR inhibitors in advanced NSCLC
- Chapter 3 : YAP/TAZ-mediated resistance to EGFR inhibitors
- Chapter 4 : Role of epithelial to mesenchymal transition in the resistant mechanism of EGFR-TKIs
- Chapter 5 : Apoptosis signaling in EGFR inhibitor resistance in NSCLC
- Chapter 6 : Control of EGFR signaling by endocytosis and endosomal trafficking
- Chapter 7 : Epithelial-mesenchymal transition and resistance to EGFR inhibitors
- Index
- A